No headlines found.
Globe Newswire (Tue, 23-Apr 7:00 AM ET)
ProQR Highlights Upcoming Presentations on Axiomer RNA Editing at ASGCT 27th Annual Meeting
Globe Newswire (Mon, 22-Apr 4:31 PM ET)
ProQR Achieves Successful Defense of New Challenge to its Axiomer IP Portfolio
Globe Newswire (Fri, 19-Apr 7:00 AM ET)
ProQR Announces Year End 2023 Operating and Financial Results
Globe Newswire (Wed, 13-Mar 7:00 AM ET)
Globe Newswire (Thu, 15-Feb 7:00 AM ET)
ProQR Therapeutics NV is a biopharmaceuticals company. It discovers and develops RNA therapeutics for patients with severe genetic rare diseases such as cystic fibrosis, Leber's congenital amaurosis type 10 and dyastrophic epidermolysis bullosa.
Proqr Therapeutics N.V. - trades on the NASDAQ stock market under the symbol PRQR.
As of May 1, 2024, PRQR stock price climbed to $2.01 with 178,827 million shares trading.
PRQR has a beta of 1.17, meaning it tends to be more sensitive to market movements. PRQR has a correlation of 0.06 to the broad based SPY ETF.
PRQR has a market cap of $143.58 million. This is considered a Micro Cap stock.
In the last 3 years, PRQR stock traded as high as $9.09 and as low as $.53.
The top ETF exchange traded funds that PRQR belongs to (by Net Assets): AVDS.
PRQR has underperformed the market in the last year with a return of -7.8%, while the SPY ETF gained +22.5%. In the last 3 month period, PRQR fell short of the market, returning -6.9%, while SPY returned +2.8%. However, in the most recent 2 weeks PRQR has outperformed the stock market by returning +0.5%, while SPY returned -0.1%.
PRQR support price is $1.84 and resistance is $2.04 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that PRQR stock will trade within this expected range on the day.